This approach is distinct from the use of 'nickases' , mutant Cas9 proteins that cleave only a single strand of double-stranded (dsDNA). Paired nickases can be used to nick opposite strands of two nearby target sites, generating what is effectively a double-strand break, and can induce substantial on-target DNA modification with reduced off-target modification 4, [12] [13] [14] . Because each of the component Cas9 nickases remains catalytically active 5, 6, 15 , and single-stranded DNA cleavage events are weakly mutagenic 16, 17 , nickases can induce genomic modification even when acting as monomers 5, 13, 18 . Moreover, because paired Cas9 nickases can efficiently induce dsDNA cleavage-derived modification events when bound up to ~100 bp apart 13, 14 , the statistical number of potential off-target sites for paired nickases is larger than that of a more spatially constrained dimeric Cas9 cleavage system. In contrast, DNA cleavage by FokI-dCas9 requires simultaneous binding of two distinct FokI-dCas9 monomers because monomeric FokI nuclease domains are not catalytically competent 18 . In principle, this approach should increase the specificity of DNA cleavage relative to wild-type Cas9 by doubling the number of specified target bases. The use of fCas9 should also result in improved specificity compared to nickases due to the inactivity of monomeric FokI-dCas9:sgRNA complexes and due to the more stringent spatial requirements for assembly of a FokI-dCas9 dimer.
RESULTS

Development of an active FokI-dCas9 fusion architecture
We began by constructing and characterizing a wide variety of FokIdCas9 fusion proteins with distinct configurations of a FokI nuclease domain, a dCas9 containing inactivating mutations D10A and H840A, and a nuclear localization sequence (NLS). We fused wildtype, homodimeric, FokI to either the N or C terminus of dCas9 and varied the location of the NLS to be at either terminus or between the The recent development of robust, predictable and user-friendly methods for the generation of sequence-specific, DNA-binding proteins has accelerated the use of genome editing for biological research 1 and therapeutic development 2 . The clustered, regularly interspaced, short palindromic repeats (CRISPR)-associated protein 9 (Cas9) system is an especially convenient approach for genome editing, as an agent for a new target site of interest can be created simply by generating the corresponding sgRNA. The 3ʹ end of the sgRNA forms a scaffold that binds Cas9 protein 3 , whereas the ~17 to 20 bases 4 at the 5ʹ end of the sgRNA pair with the target DNA to determine DNA cleavage specificity (Fig. 1) . Provided that the target sequence is adjacent to a short 3ʹ motif-the protospacer adjacent motif (PAM) required for initial binding and Cas9 activation 5 -any DNA locus can in principle be targeted. In cells, doublestrand breaks induced by targeted Cas9:sgRNA complexes enable either functional gene knockout through nonhomologous end joining (NHEJ) or alteration of a target locus to virtually any sequence through homology-directed repair with an exogenous DNA template 3, 6, 7 .
The usefulness of Cas9 for research and therapeutic applications may be limited by its ability to cleave off-target genomic sites [8] [9] [10] [11] [12] . We hypothesized that engineering Cas9 variants to cleave DNA only when two simultaneous, adjacent Cas9:DNA binding events take place could substantially improve specificity because the likelihood of two adjacent off-target binding events is much smaller than the likelihood of a single off-target binding event (approximately 1/n 2 versus 1/n). This approach is analogous to that previously developed for dimeric zinc-finger nucleases (ZFNs) and TALENs. Based on those examples, we speculated that fusing the FokI restriction endonuclease cleavage domain to a catalytically dead Cas9 (dCas9) could create an obligate dimeric Cas9 that would cleave DNA only when two distinct FokI-dCas9:sgRNA complexes bind to adjacent sites ("half-sites") with particular spacing constraints (Fig. 1a) . Genome editing by Cas9, which cleaves double-stranded DNA at a sequence programmed by a short single-guide RNA (sgRNA), can result in off-target DNA modification that may be detrimental in some applications. To improve DNA cleavage specificity, we generated fusions of catalytically inactive Cas9 and FokI nuclease (fCas9). DNA cleavage by fCas9 requires association of two fCas9 monomers that simultaneously bind target sites ~15 or 25 base pairs apart. In human cells, fCas9 modified target DNA sites with >140-fold higher specificity than wild-type Cas9 and with an efficiency similar to that of paired Cas9 'nickases', recently engineered variants that cleave only one DNA strand per monomer. The specificity of fCas9 was at least fourfold higher than that of paired nickases at loci with highly similar off-target sites. Target sites that conform to the substrate requirements of fCas9 occur on average every 34 bp in the human genome, suggesting the versatility of this approach for highly specific genome-wide editing.
npg a r t i c l e s
Most of the initial FokI-dCas9 fusion variants were inactive or very weakly active (Supplementary Fig. 3 ). Only the NLS-FokI-dCas9 architecture resulted in a frequency of GFP-negative cells that was substantially higher than what was observed in the corresponding no-sgRNA control when used in orientation A (with PAMs distal from the spacer) (Supplementary Fig. 3a) . By contrast, NLS-FokI-dCas9 activity above background was not detected when used with sgRNA pairs in orientation B, with PAMs adjacent to the spacer (Supplementary Fig. 3b) . Examination of the recently reported Cas9 structures 21, 22 reveals that the Cas9 N terminus protrudes from the RuvC domain, which contacts the 5ʹ end of the sgRNA:DNA duplex. We speculate that this arrangement places an N-terminally fused FokI distal from the PAM, resulting in a preference for sgRNA pairs with PAMs distal from the cleaved spacer (Fig. 1a) . Further, examination of the structure of the C terminus of dCas9 suggests that access to the spacer by FokI C-terminal fusions may require longer linkers to span the PI and RuvC Cas9 domains with paired sgRNAs in orientation A, or to span the REC1 domain of Cas9 and sgRNA stem loops with sgRNAs in orientation B. Although other FokI-dCas9 fusion pairings and the other sgRNA orientation in some cases showed modest activity (Supplementary Fig. 3 ), we chose NLSFokI-dCas9 with sgRNAs in orientation A for further development.
Optimizing and validating the NLS-FokI-dCas9 architecture Next we optimized the protein linkers between the NLS and FokI domain and between the FokI domain and dCas9 in the NLS-FokIdCas9 architecture. We tested 17 linkers with a wide range of amino acid compositions, predicted flexibilities and lengths varying from 9 to 21 residues (Supplementary Fig. 4a ). For the linker between the FokI domain and dCas9, the highest levels of genomic GFP modification was observed for the proteins with a flexible 18-residue linker (GGS) 6 and a 16-residue "XTEN" linker, which was based on a previously reported engineered protein with an open, extended conformation 23 (FokI-L8 in Supplementary Fig. 4a,b and Supplementary Results). Many of the FokI-dCas9 linkers tested including the optimal XTEN linker resulted in nucleases with a marked preference for spacer lengths of ~15 and ~25 bp between half-sites, with all other spacer lengths, including 20 bp, showing substantially lower activity (Supplementary Fig. 4b ). This pattern of linker preference is consistent with a model in which the FokI-dCas9 two domains (Fig. 1b and Supplementary Notes). We further varied the length of the linker sequence as either one or three repeats of GlyGly-Ser (GGS) between the FokI and dCas9 domains. As previously developed dimeric nuclease systems are sensitive to the length of the spacer sequence between half-sites 19, 20 , we also tested a wide range of spacer sequence lengths between two sgRNA binding sites within a test target gene, Emerald GFP (Life Technologies) (referred to hereafter as GFP) (Fig. 1c,d and Supplementary Fig. 1 ).
We chose two sets of sgRNA binding-site pairs with different orientations within GFP. One set placed the pair of NGG PAM sequences distal from the spacer sequence, with the 5ʹ end of the sgRNA adjacent to the spacer (orientation A) (Fig. 1c) , whereas the other placed the PAM sequences immediately adjacent to the spacer (orientation B) (Supplementary Fig. 1 ). In total, seven pairs of sgRNAs were suitable for orientation A and six were suitable for orientation B. By pairwise combination of the sgRNA targets, we tested spacer lengths in both dimer orientations, ranging from 5 to 43 bp in orientation A, and 4 to 42 bp in orientation B. In total, 216 pairs of FokI-dCas9:sgRNA complexes were generated and tested, exploring four fusion architectures, 17 protein linker variants (described below), both sgRNA orientations and 13 spacer lengths between half-sites.
To assay the activities of these candidate FokI-dCas9:sgRNA pairs, we used a previously described flow cytometry-based fluorescence assay 4, 9 in which DNA cleavage and NHEJ of a stably integrated constitutively expressed GFP gene in HEK293 cells leads to loss of cellular fluorescence (Supplementary Fig. 2 ). For comparison, we assayed the initial set of FokI-dCas9 variants side-by-side with the corresponding Cas9 nickases and wild-type Cas9 in the same expression plasmid across both sgRNA spacer orientation sets A and B. Cas9 protein variants and sgRNA were generated in cells by transient co-transfection of the corresponding Cas9 protein expression plasmids together with the appropriate pair of sgRNA expression plasmids. The FokI-dCas9 variants, nickases and wild-type Cas9 all targeted identical DNA sites using identical sgRNAs. Although this assay showed a consistent ~5% background signal in the absence of sgRNA, it enabled the rapid assessment of many fusion constructs, sgRNA orientations and DNA spacer lengths to identify active constructs for further optimization. npg a r t i c l e s fusions must bind to opposite faces of the DNA double helix to cleave DNA, with optimal binding taking place ~1.5 or 2.5 helical turns apart. The variation of the NLS-FokI linkers did not strongly affect nuclease performance, especially when combined with the XTEN FokI-dCas9 linker ( Supplementary Fig. 4b and Supplementary Results).
The NLS-GGS-FokI-XTEN-dCas9 construct consistently exhibited the highest activity among the tested candidates, inducing loss of GFP in ~10% of cells over background, compared to ~15% and ~25% for Cas9 nickases and wild-type Cas9 nuclease, respectively (Fig. 2a) . All subsequent experiments were done using this construct, hereafter referred to as fCas9. To confirm the ability of fCas9 to efficiently modify genomic target sites, we used the T7 endonuclease I Surveyor assay to measure the amount of mutation at each of seven target sites within the integrated GFP gene in HEK293 cells treated with fCas9, Cas9 nickase or wildtype Cas9, and either of two distinct sgRNAs in orientation A or no sgRNAs as a negative control. Consistent with our flow cytometry-based studies, fCas9 was able to modify the GFP target sites with optimal spacer lengths of ~15 or ~25 bp at a rate of ~20%, comparable to the efficiency of nickase-induced modification and approximately twothirds that of wild-type Cas9 ( Fig. 2a-c) .
Modification of endogenous genomic targets by optimized fCas9
Next, we evaluated the ability of the optimized fCas9 to modify 14 distinct endogenous genomic loci in five genes by Surveyor assay. AAVS1 (one site), CLTA (two sites), EMX (two sites), HBB (six sites) and VEGF (three sites) were targeted with two sgRNAs per site in orientation A spaced at various lengths ( Supplementary Fig. 5 ). Consistent with the results of the experiments targeting GFP, at appropriately spaced target half-sites, fCas9 induced efficient modification of all five genes, with efficiencies ranging from 8% to 22% (Fig. 2d-h and Supplementary Fig. 6 ). With the sgRNA spacer lengths resulting in the highest modification at each of the six genes targeted (including GFP), fCas9 induced on average 14.9% (±6.0% s.d.) modification, whereas Cas9 nickase and wild-type Cas9 induced on average 20.6% (±5.6% s.d.) and 28.2% (±6.2% s.d.) modification, respectively. Because decreasing the amount of Cas9 expression plasmid and sgRNA expression plasmid during transfection generally did not proportionally decrease genomic modification activity for Cas9 nickase and fCas9 (Supplementary Fig. 7a-c) , expression was likely not limiting under the conditions tested.
Stringent spatial requirements of fCas9-mediated DNA cleavage As the sgRNA requirements of fCas9 potentially reduce the number of potential off-target substrates of fCas9, we compared the effect of guide RNA orientation on the ability of fCas9, Cas9 nickase and wildtype Cas9 to cleave target GFP sequences. Consistent with previous reports [12] [13] [14] , Cas9 nickase efficiently cleaved targets when guide RNAs
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The observed rate of nickase-induced DNA modification did not account for the much higher GFP disruption signal in the flow cytometry assay (Supplementary Fig. 9b ). Because the sgRNAs that induced GFP signal loss with Cas9 nickase (sgRNAs G1 and G3) both target the nontemplate strand of the GFP gene, and because targeting the nontemplate strand with dCas9 in the coding region of a gene is known to mediate efficient transcriptional repression 24 , we speculate that Cas9 nickase combined with the G1 or G3 sgRNAs induced substantial transcriptional repression, in addition to a low level of genome modification. The same effect was not seen for fCas9, suggesting that fCas9 may be more easily displaced from DNA by transcriptional machinery. Taken together, these results indicate that fCas9 can modify genomic DNA efficiently and in a manner that requires simultaneous engagement of two guide RNAs targeting adjacent sites, unlike the ability of wild-type Cas9 and Cas9 nickase to cleave DNA when bound to a sgRNA.
The above results collectively reveal much more stringent spacer, sgRNA orientation, and guide RNA pairing requirements for fCas9 compared with Cas9 nickase. In contrast with fCas9 ( Supplementary  Fig. 10 ), Cas9 nickase cleaved sites across all spacers assayed (5 to 47 bp in orientation A and 4 to 42 bp in orientation B in this work) (Fig. 2a,c and Supplementary Fig. 8a,b) . These observations are consistent with previous reports of Cas9 nickases modifying sites targeted by sgRNAs with spacer lengths up to 100 bp apart 13, 14 . The more stringent spacer and sgRNA orientation requirements of fCas9 compared with Cas9 nickase reduces the number of potential genomic off-target sites of the former by approximately tenfold (Supplementary Table 1) . Although the more stringent spacer requirements of fCas9 also reduce the number were bound either in orientation A or orientation B, similar to wild-type Cas9 (Supplementary Fig. 8a,b) . In contrast, fCas9 only cleaved the GFP target when guide RNAs were aligned in orientation A (Fig. 2a-c and Supplementary Fig. 8a,b) . This orientation requirement further limits opportunities for undesired off-target DNA cleavage.
No modification was observed by GFP disruption or Surveyor assay when any of four single sgRNAs were expressed individually with fCas9, as expected because two simultaneous binding events are required for FokI activity (Fig. 2b and Supplementary Fig. 9 ). By contrast, GFP gene disruption resulted from expression of any single sgRNA with wild-type Cas9 (as expected) and, in the case of two single sgRNAs, with Cas9 nickase (Fig. 3a) . High-throughput sequencing to detect indels at the GFP target site in cells treated with paired sgRNAs and fCas9, Cas9 nickase, or wild-type Cas9 revealed the expected substantial level of modification ranging from 2.3% to 14.3% of sequence reads. Modification by fCas9 in the presence of any of the four single sgRNAs was not detected above background signal (ranging from <0.01% to 0.073% modification), consistent with the requirement of fCas9 to engage two sgRNAs to cleave DNA. By contrast, Cas9 nickases in the presence of single sgRNAs resulted in modification levels ranging from 0.05% to 0.16% at the target site (Fig. 3a) . The detection of bona fide indels at target sites following Cas9 nickase treatment with single sgRNAs confirms the mutagenic potential of genomic DNA nicking, consistent with previous reports 3, 12, 13, 16, 17 . These results collectively demonstrate that Cas9 nickase can induce genomic DNA modification in the presence of a single sgRNA, in contrast with the absence of single-sgRNA modification by fCas9. 5ʹ-CCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGG-3ʹ  G1  CCGCGCCGAGGTGAAGTTCGAGG  G3  CCCTGGTGAACCGCATCGAGCTG  G5  GCTGAAGGGCATCGACTTCAAGG  G7  CAAGGAGGACGGCAACATCCTGG  G1+5 CCGCGCCGAGGTGAAGTTCGAGG----------25 bp----------GCTGAAGGGCATCGACTTCAAGG  G3+7 CCCTGGTGAACCGCATCGAGCTG-----14 bp----CAAGGAGGACGGCAACATCCTGG
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Indel modi cation frequency (%) Indel modi cation frequency (%) Indel modi cation frequency (%) Figure 3 DNa modification specificity of fcas9, cas9 nickase, and wild-type cas9. (a) results from high-throughput sequencing of GFP ontarget sites amplified from 150 ng genomic DNa isolated from human cells treated with a plasmid expressing wild-type cas9, cas9 nickase or fcas9; and either a plasmid expressing a single sgrNa (G1, G3, G5 or G7), or two plasmids each expressing a different sgrNa (G1+G5 or G3+G7). as a negative control, transfection and sequencing were done in triplicate as above without any sgrNa expression plasmids. sequences with more than one insertion or deletion at the GFP target site (the start of the G1 binding site to the end of the G7 binding site) were considered indels. indel percentages are the number of indels observed, divided by the total number of sequences. although wildtype cas9 produced indels across all sgrNa treatments, fcas9 and cas9 nickase produced indels efficiently (>1%) only when paired sgrNas were present. indels induced by fcas9 and single sgrNas were not detected at a frequency above that of the no-grNa control, whereas cas9 nickase and single sgrNas modified the target GFP sequence at an average rate of 0.12%. Table 3 ). npg a r t i c l e s of potential targetable sites, sequences that conform to the fCas9 spacer and dual PAM requirements exist in the human genome on average once every 34 bp (9.2 × 10 7 sites in 3.1 × 10 9 bp) (Supplementary Table 1 ). We also anticipate that the growing number of Cas9 homologs with different PAM specificities 25 will further increase the number of targetable sites using the fCas9 approach.
Improved specificity of fCas9 at endogenous off-target sites To evaluate the DNA cleavage specificity of fCas9, we measured the modification of known Cas9 off-target sites of CLTA, EMX and VEGF genomic target sites 4, 8, 9, 14 . The target site and its corresponding known off-target sites (Supplementary Table 2 ) were amplified from genomic DNA isolated from HEK293 cells treated with fCas9, Cas9 nickase or wild-type Cas9 and two sgRNAs spaced 19 bp apart targeting the CLTA site, two sgRNAs spaced 23 bp apart targeting the EMX site, two sgRNAs spaced 14 bp apart targeting the VEGF site, or two sgRNAs targeting an unrelated site (GFP) as a negative control. In total 11 off-target sites were analyzed by high-throughput sequencing (Supplementary Notes). Sequences containing insertions or deletions of two or more base pairs in potential genomic off-target sites and present in significantly greater numbers (P < 0.005, Fisher's exact test) in the target sgRNA-treated samples versus the control sgRNA-treated samples were considered Cas9 nuclease-induced genome modifications. For all 11 off-target sites initially assayed, fCas9 did not result in any detectable genomic off-target modification within the sensitivity limit of our assay (<0.002%, Supplementary Results; see further discussion of VEGF off-target site 1 below), while demonstrating substantial on-target modification efficiencies of 5% to 10% (Fig.  3b-d and Supplementary Table 3a-c) . The detailed inspection of fCas9-modified VEGF on-target sequences (Supplementary Fig. 11a ) revealed a prevalence of deletions ranging from two to dozens of base pairs consistent with cleavage occurring in the DNA spacer between the two target binding sites. For each target site at CLTA, EMX and VEGF, fCas9 predominantly induces deletions with insertions representing <5% of all modifications. This prevalence of deletions is also observed with TALENs, which have similar spacer-length preferences 26 . By contrast, genomic off-target DNA cleavage was observed for wildtype Cas9 at all 11 sites assayed. Using the detection limit of the assay as an upper bound for off-target fCas9 activity, we calculated that fCas9 has a much lower off-target modification rate than wild-type Cas9 nuclease. At the 11 off-target sites modified by wild-type Cas9 nuclease, fCas9 resulted in on-target:off-target modification ratios at least 140-fold higher than that of wild-type Cas9 (Fig. 3b-d) .
Consistent with previous reports 4, 12, 14 , paired Cas9 nickases also induced substantially fewer off-target modification events (1/11 off-target sites modified at a detectable rate) than wild-type Cas9. An initial highthroughput sequencing assay revealed significant (P < 10 -3 , Fisher's exact test) modification induced by Cas9 nickases in 0.024% of sequences at VEGF off-target site 1. This genomic off-target site was not modified by fCas9 despite similar VEGF on-target modification efficiencies of 12.3% for Cas9 nickase and 10.4% for fCas9 (Fig. 3d and Supplementary Table  3c) . Because Cas9 nickase-induced modification levels were within an order of magnitude of the limit of detection and fCas9 modification levels were undetected, we repeated the experiment with a larger input DNA samples and a greater number of sequence reads (low input of 150 ng versus high input 600 ng genomic DNA and >8 × 10 5 versus >23 × 10 5 reads for the initial and second trial, respectively) to detect off-target cleavage at this site by Cas9 nickase or fCas9 (Supplementary Notes).
From this deeper interrogation, we observed Cas9 nickase and fCas9 to both significantly modify (P < 10 -5 , Fisher's exact test) VEGF off-target site 1 (Fig. 3e, Supplementary Table 3d and Supplementary Fig. 11b ).
For both experiments interrogating the modification rates at VEGF offtarget site 1, fCas9 exhibited a greater on-target/off-target DNA modification ratio than that of Cas9 nickase (>5,150 and 1,650 for fCas9, versus 510 and 1,230 for Cas9 nickase, Fig. 3e) .
To further investigate differences in specificity between fCas9 and Cas9 nickases, three new target sites (sites A, B, and C) were chosen in the human genome that each had potential genomic off-target sites containing one identical or nearly identical half-site (Supplementary Table 4) . The three on-target sites and their highly similar off-target sites were amplified and sequenced from cells treated with a mock transfection of a GFP expression plasmid, fCas9, or Cas9 nickases and either two sgRNAs spaced 15 bp apart targeting genomic site A, two sgRNA spaced 24 bp apart targeting genomic site B, or two sgRNA spaced 23 bp apart targeting genomic site C. At these three sites fCas9 demonstrated greater than fourfold average increase in on-target/off-target genome modification activity compared to Cas9 nickases (Fig. 4 and Supplementary Table  5 ). These results suggest that for highly similar sets of on-and off-target sites, as may be found with repetitive genomic loci, pseudogenes or homologous gene families, fCas9 can result in improved genome modification specificity over that of Cas9 nickases.
DISCUSSION
In this work, we developed fCas9, an obligate dimeric FokI-dCas9 nuclease architecture. The fCas9 nuclease modified all 11 genomic loci tested with sgRNA pairs spaced ~15 bp or ~25 bp apart, demonstrating the generality of using fCas9 to induce genomic modification in human cells. The use of fCas9 is straightforward, requiring only that PAM sequences be present with an appropriate spacing and orientation, and using the same sgRNA architecture as wild-type Cas9 or Cas9 nickases. Although modification with fCas9 was generally less efficient than with wild-type Cas9, fCas9 was consistently more specific, producing substantially fewer off-target modification 
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Indel modi cation frequency (%) Indel modi cation frequency (%) Figure 4 Genomic DNa modification specificity of fcas9 and cas9 nickase at genomic sites with highly similar off-target sites. (a-c) the indel mutation frequency from high-throughput DNa sequencing of amplified genomic on-target sites and off-target sites (Supplementary events. The observed low off-target/on-target modification ratios of fCas9 were at least 140-fold lower than that of wild-type Cas9 and from 1.3-to 8.8-fold lower than that of paired Cas9 nickases. These improvements likely arise from the distinct mode of action of dimeric FokI, which cleaves DNA only if two sites are occupied simultaneously by two FokI domains at a specified distance (here, ~15 bp or ~25 bp apart) and in a specific half-site orientation. Indeed, when presented with only a single sgRNA (Fig. 3a) , or a single matching half-site at off-target genomic loci (Fig. 4) , fCas9 was unable to modify DNA. Given our use of plasmid transfection in this study, more efficient gene delivery methods such as nucleofection may offer higher fCas9 modification efficiency. The only observed off-target DNA modification by fCas9 in this study was the modification of the VEGF off-target site 1. On either side of the VEGF off-target site 1, there exist no other sites with six or fewer mutations from either of the two half-sites of the VEGF on-target sequence. We speculate that the first 11 bases of one sgRNA (V2) might hybridize to the single-stranded DNA freed by canonical Cas9:sgRNA binding within VEGF off-target site 1 (Supplementary Fig. 11c ). Through this sgRNA:DNA hybridization it is possible that a second Cas9 nickase or fCas9 could be recruited to modify this off-target site at an extremely rare, but detectable frequency.
A recent report 27 demonstrates the promiscuity of dCas9 binding to sequences containing only an NGG PAM and a "seed" sequence as short at five bases immediately 5ʹ of the PAM. A search of the sequence surrounding VEGF off-target site 1 identified a single site of this type, with a single mismatch within the six bases 5ʹ of an NGG PAM (Supplementary Fig. 11d ). This potential site corresponds to an untested sgRNA pair orientation, and is likely a very inefficient substrate for fCas9 cleavage. Judicious sgRNA pair design could eliminate either of these potential modes of off-target DNA cleavage at sites similar to VEGF off-target site 1. The promiscuity of dCas9 binding at short seed-PAM sequences may be mitigated by the requirement of fCas9 to assemble on two dCas9 binding sites with very specific spacer constraints and PAM orientations.
The low off-target activity of fCas9 may enable applications of Cas9:sgRNA-based technologies that require a very high degree of target specificity, such as ex vivo or in vivo therapeutic modification of human cells. This work also provides a foundation for future studies to characterize in greater detail and further improve the DNA cleavage activity and specificity of fCas9 in vitro and in vivo. For example, the use of recently described orthogonal Cas9 homologs 25 coupled with obligate heterodimeric FokI variants 28 may offer additional specificity gains.
METHODS
Methods and any associated references are available in the online version of the paper. expression + sgRNA expression plasmid), 700/250, 350/125, 175/62.5, 88/31 ng of Cas9 expression plasmid/ng of sgRNA expression plasmid were combined with inert carrier plasmid, pUC19 (NEB), as necessary to reach a total of 950 ng transfected plasmid DNA.
Genomic DNA was isolated from cells 2 d after transfection using a genomic DNA isolation kit, DNAdvance Kit (Agencourt). Briefly, cells in a 48-well plate were incubated with 40 μl of trypsin for 5 min at 37 °C. 160 μl of DNAdvance lysis solution was added and the solution incubated for 2 h at 55 °C and the subsequent steps in the Agencourt DNAdvance kit protocol were followed. 40 ng of isolated genomic DNA was used as template to PCR amplify the targeted genomic loci with flanking Survey primer pairs specified in the Supplementary Notes. PCR products were purified with a QIAquick PCR Purification Kit (Qiagen) and quantified with Quant-iT PicoGreen dsDNA Kit (Life Technologies). 250 ng of purified PCR DNA was combined with 2 μl of NEBuffer 2 (NEB) in a total volume of 19 μl and denatured then re-annealed with thermocycling at 95 °C for 5 min, 95-85 °C at 2 °C/s; 85-20 °C at 0.2 °C/s. The re-annealed DNA was incubated with 1 μl of T7 Endonuclease I (10 U/μl, NEB) at 37 °C for 15 min. 10 μl of 50% glycerol was added to the T7 Endonuclease reaction and 12 μl was analyzed on a 5% TBE 18-well Criterion PAGE gel (Bio-Rad) electrophoresed for 30 min at 150 V, then stained with 1× SYBR Gold (Life Technologies) for 30 min. Cas9-induced cleavage bands and the uncleaved band were visualized on an AlphaImager HP (Alpha Innotech) and quantified using ImageJ software 30 . The peak intensities of the cleaved bands were divided by the total intensity of all bands (uncleaved + cleaved bands) to determine the fraction cleaved, which was used to estimate gene modification levels as previously described 31 . For each sample, transfections and subsequent modification measurements were performed in triplicate on different days.
High-throughput sequencing of genomic modifications. HEK293-GFP stable cells were transfected with plasmids expressing Cas9 and sgRNAs. Generally, 700 ng of Cas9 expression plasmid (encoding either fCas9, Cas9 nickase or Cas9 nuclease) plus 250 ng of a single plasmid expressing a pair of sgRNAs were transfected. (See Supplementary Fig. 7 and Supplementary Table 3 for additional details.) Genomic DNA was isolated as above and pooled from three biological replicates. 150 ng or 600 ng of pooled genomic DNA was used as template to amplify by PCR the on-target and off-target genomic sites with flanking HTS primer pairs specified in the Supplementary Notes. Relative amounts of crude PCR products were quantified by gel electrophoresis, and samples treated with different sgRNA pairs or Cas9 nuclease types were separately pooled in equimolar concentrations before purification with the QIAquick PCR Purification Kit (Qiagen). ~500 ng of pooled DNA was run on a 5% TBE 18-well Criterion PAGE gel (Bio-Rad) for 30 min at 200 V, and DNAs of length ~125 bp to ~300 bp were isolated and purified by QIAquick PCR Purification Kit (Qiagen). Purified DNA was PCR amplified with primers containing sequencing adaptors, purified and sequenced on a MiSeq highthroughput DNA sequencer (Illumina) as described previously 8 .
Data analysis. Illumina sequencing reads were filtered and parsed with scripts written in Unix Bash as outlined in Supplementary Notes. The source code was published previously 20 . DNA sequences will be deposited in NCBI's Sequencing Reads Archive (SRA). Sample sizes for sequencing experiments were maximized (within practical experimental considerations) to ensure the greatest power to detect effects. Statistical analyses for Cas9-modified genomic sites in Supplementary Table 3 were performed as previously described 32 with multiple comparison correction using the Bonferroni method.
